Abstract:Importance: Meningioma is the most common subsequent neoplasm following cranial irradiation among survivors of childhood cancer, but there are still uncertainties regarding the magnitude of the radiation dose-response association, potential modifiers of radiation risks, and the role of chemotherapy. Objective: To evaluate meningioma risk in survivors of childhood cancer following radiotherapy and chemotherapy and identify possible modifying factors of radiation-associated risk. Design, setting, and participants: This international case-control study pooled data from 4 nested case-control studies of survivors of childhood cancer diagnosed between 1942 and 2000, followed through 2016. Cases were defined as participants diagnosed with a subsequent meningioma. Controls were matched to cases based on sex, age at first cancer diagnosis, and duration of follow-up. Data were analyzed from July 2019 to June 2022. Exposures: Radiation dose (Gy) to the meningioma site and cumulative chemotherapy doses, including intrathecal and systemic methotrexate doses. Main outcomes and measures: The main outcome was subsequent meningioma, assessed using odds ratios (ORs) and excess odds ratios per gray (EOR/Gy). Results: The analysis included 273 survivors of childhood cancer who developed meningioma (cases) and 738 survivors who did not (controls), with a total of 1011 individuals (median [IQR] age at first cancer diagnosis 5.0 [3.0-9.2] years; 599 [59.2%] female). Median (IQR) time since first cancer was 21.5 (15.0-27.0) years. Increasing radiation dose was associated with increased risk of meningioma (EOR/Gy, 1.44; 95% CI, 0.62-3.61), and there was no evidence of departure from linearity (P = .90). Compared with survivors who were not exposed to radiation therapy, those who received doses of 24 Gy or more had more than 30-fold higher odds of meningioma (OR, 33.66; 95% CI, 14.10-80.31). The radiation dose-response association was significantly lower among patients treated at age 10 years or older compared with those treated before age 10 years (EOR/Gy, 0.57; 95% CI, 0.18-1.91 vs 2.20; 95% CI, 0.87-6.31; P for heterogeneity = .03). Risk associated with radiation remained significantly elevated 30 years after exposure (EOR/Gy, 3.76; 95% CI, 0.77-29.15). We found an increased risk of meningioma among children who had received methotrexate (OR, 3.43; 95% CI, 1.56-7.57), but no evidence of a dose-response association or interaction with radiation dose. Conclusions and relevance: These findings suggest that the meninges are highly radiosensitive, especially for children treated before age 10 years. These results support the reduction in whole-brain irradiation over recent decades and the prioritization of approaches that limit radiation exposure in healthy tissue for children. The persistence of elevated risks of meningiomas for 30 years after cranial radiotherapy could help inform surveillance guidelines.

301 Even Heterozygous Loss of CDKN2A B Greatly Accelerates Recurrence in Aggressive Meningioma

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

Path-04. The Prognostic Impact Of Cdkn2A/B Heterozygous Deletions In Meningioma- Insights Of A Multicenter Analysis

Surg-03. Gene Expression Changes Associated With Recurrence After Gross Total Resection Of Newly Diagnosed Who Grade 1 Meningioma

A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence

Biom-68. Outcomes In Patients With High-Grade Meningioma (Hgm): A Multi-Institutional Study

Biom-16. A Targeted Gene Expression Biomarker Predicts Low Grade Meningioma Recurrence And Overall Survival

Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma

Path-32. The Prognostic Impact Of Cdkn2A/B Heterozygous Deletions In Idh-Mutant Glioma

Biom-01. Cdkn2A Homozygous Deletion Has Stronger Prognostic Power Thanidh Mutation In Cns Who Grade 4 Gliomas

Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk

PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas

1245 Malignant Meningioma Survival, Recurrence and Functional Outcomes in an International Multicenter Cohort

Biom-60. Understanding The Intersection Of Race, Sex, And Genomic Profiles In Meningioma Pathophysiology

Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas

WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index

CDKN2A Homozygous Deletion Is a Stronger Predictor of Outcome than IDH1/2-Mutation in CNS WHO Grade 4 Gliomas

379 Meningioma Molecular Groups Predict Response to Adjuvant Radiotherapy Following Surgery

Epco-39. Multiomic And Clinical Analysis Of Multiply Recurrent Meningiomas Reveals Risk Factors, Underlying Biology, And Insights Into Evolution

Molecular landscapes of longitudinal NF2/22q and non‐NF2/22q meningiomas show different life histories

Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer